Linagliptin Stada Arzneimittel Ag (Linagliptin)

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus, helping to improve glycaemic control when combined with diet and exercise.

• Type 2 diabetes mellitus: improves blood glucose levels by enhancing insulin secretion and reducing glucagon release.

• Linagliptin selectively inhibits the dipeptidyl peptidase‑4 enzyme, which results in increased circulating levels of the incretin hormones GLP‑1 and GIP. Elevated incretins promote glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, thereby lowering post‑prandial and fasting blood glucose concentrations.

Linagliptin may cause a range of adverse reactions, some of which are more frequently reported than others.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nasal passages and throat.
• Headache: transient head discomfort of varying intensity.
• Upper respiratory tract infection: symptoms such as cough, sore throat, or congestion.
• Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain that may indicate inflammation of the pancreas.
• Severe allergic reactions: including rash, angioedema, or anaphylaxis.
• Hepatic injury: abnormal liver function tests or jaundice.
• Bullous pemphigoid: rare skin disorder characterized by blistering lesions.

Before initiating linagliptin therapy, certain precautions should be considered to ensure safe use.

• Renal function monitoring: assess kidney status, especially in patients with impairment.
• Hepatic function monitoring: evaluate liver enzymes periodically.
• Cardiovascular risk assessment: consider in patients with existing heart disease.
• Use with caution in the elderly: increased susceptibility to adverse events.
• Avoid in patients with known hypersensitivity to linagliptin or excipients.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Linagliptin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
• Strong CYP3A4 inducers (e.g., rifampicin): may reduce linagliptin effectiveness.
• Insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

• Diuretics: possible alterations in fluid balance affecting glucose control.
• Antihypertensive agents: monitor blood pressure as glycaemic changes may occur.
• Other antidiabetic drugs: assess for additive glucose‑lowering effects.